Back to search

Article

The amount of circulating DNA and the presence of TP53 mutations in plasma predict clinical outcome of renal cancer patients treated with immunotherapy and VEGFR-TKIs

2022-05-27

Abstract excerpt

<title>Abstract</title> <p><bold>Background </bold>Despite the increasing treatments options, reliable biomarkers of response are still missing for patients affected by metastatic renal cell carcinoma (mRCC). <bold>Methods </bold>Patients affected by mRCC undergoing standard first line treatment were enrolled. Twelve ml of blood were drawn at treatment baseline and circulating free DNA (cfDNA) was extracted from...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
effe5c75-5edc-5633-bc1c-4852cb1ad9c7
DOI
10.21203/rs.3.rs-1594180/v2
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
The amount of circulating DNA and the presence of TP53 mutations in plasma predict clinical outcome of renal cancer patients treated with immunotherapy and VEGFR-TKIsDOI 10.21203/rs.3.rs-1594180/v2
Increased level and fragmentation of plasma circulating cell-free DNA are diagnostic and prognostic markers for renal cell carcinomaSemantic proximity
Diagnostic and prognostic value of circulating tumor-related DNA in cancer patients.Semantic proximity
Clinical significance of the mutational landscape and fragmentation of circulating tumor DNA in renal cell carcinomaSemantic proximity
What do we need to obtain high quality circulating tumor DNA (ctDNA) for routine diagnostic test in oncology? – Considerations on pre-analytical aspects by the IFCC workgroup cfDNASemantic proximity
Complementary Role of Circulating Tumor DNA Assessment and Tissue Genomic Profiling in Metastatic Renal Cell Carcinoma.Semantic proximity
Recent advances in circulating nucleic acids in oncologySemantic proximity
Emerging Molecular Technologies in Renal Cell Carcinoma: Liquid BiopsySemantic proximity
Concurrent tissue and circulating tumor DNA analysis in renal cell carcinoma: insights from a multimodal database.Semantic proximity
cfDNA Sequencing: Technological Approaches and Bioinformatic IssuesSemantic proximity
The Clinical Impact of Quantitative Cell-free DNA, KRAS, and BRAF Mutations on Response to Anti-EGFR Treatment in Patients with Metastatic Colorectal Cancer.Semantic proximity
Treatment monitoring of colorectal cancer by integrated analysis of plasma concentration and sequencing of circulating tumor DNA.Semantic proximity
[Biomarkers of response to molecular targeted therapy in renal cell carcinoma].Semantic proximity
Select a neighboring publication to make it the new centre.